Canada · Delayed Price · Currency is CAD NexgenRx Statistics
Total Valuation
NexgenRx has a market cap or net worth of CAD 25.60 million. The enterprise value is 22.84 million.
| Market Cap | 25.60M |
| Enterprise Value | 22.84M |
Important Dates
The last earnings date was Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | Dec 17, 2025 |
Share Statistics
NexgenRx has 71.12 million shares outstanding. The number of shares has increased by 0.68% in one year.
| Current Share Class | 71.12M |
| Shares Outstanding | 71.12M |
| Shares Change (YoY) | +0.68% |
| Shares Change (QoQ) | -15.59% |
| Owned by Insiders (%) | 36.55% |
| Owned by Institutions (%) | n/a |
| Float | 44.82M |
Valuation Ratios
The trailing PE ratio is 25.71.
| PE Ratio | 25.71 |
| Forward PE | n/a |
| PS Ratio | 1.43 |
| PB Ratio | 3.36 |
| P/TBV Ratio | 7.33 |
| P/FCF Ratio | 5.47 |
| P/OCF Ratio | 5.15 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.92, with an EV/FCF ratio of 4.88.
| EV / Earnings | 21.57 |
| EV / Sales | 1.27 |
| EV / EBITDA | 8.92 |
| EV / EBIT | 10.23 |
| EV / FCF | 4.88 |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.13 |
| Quick Ratio | 0.19 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | 0.08 |
| Interest Coverage | 83.69 |
Financial Efficiency
Return on equity (ROE) is 16.92% and return on invested capital (ROIC) is 31.75%.
| Return on Equity (ROE) | 16.92% |
| Return on Assets (ROA) | 4.16% |
| Return on Invested Capital (ROIC) | 31.75% |
| Return on Capital Employed (ROCE) | 28.24% |
| Weighted Average Cost of Capital (WACC) | 6.73% |
| Revenue Per Employee | 896,621 |
| Profits Per Employee | 52,937 |
| Employee Count | 20 |
| Asset Turnover | 0.53 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NexgenRx has paid 645,841 in taxes.
| Income Tax | 645,841 |
| Effective Tax Rate | 33.37% |
Stock Price Statistics
The stock price has increased by +24.14% in the last 52 weeks. The beta is 0.45, so NexgenRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +24.14% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 0.32 |
| Relative Strength Index (RSI) | 50.78 |
| Average Volume (20 Days) | 35,320 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NexgenRx had revenue of CAD 17.93 million and earned 1.06 million in profits. Earnings per share was 0.01.
| Revenue | 17.93M |
| Gross Profit | 14.93M |
| Operating Income | 2.23M |
| Pretax Income | 1.94M |
| Net Income | 1.06M |
| EBITDA | 2.46M |
| EBIT | 2.23M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 4.78 million in cash and 365,555 in debt, with a net cash position of 4.41 million or 0.06 per share.
| Cash & Cash Equivalents | 4.78M |
| Total Debt | 365,555 |
| Net Cash | 4.41M |
| Net Cash Per Share | 0.06 |
| Equity (Book Value) | 7.62M |
| Book Value Per Share | 0.08 |
| Working Capital | 3.71M |
Cash Flow
In the last 12 months, operating cash flow was 4.98 million and capital expenditures -296,044, giving a free cash flow of 4.68 million.
| Operating Cash Flow | 4.98M |
| Capital Expenditures | -296,044 |
| Depreciation & Amortization | 227,343 |
| Net Borrowing | -110,557 |
| Free Cash Flow | 4.68M |
| FCF Per Share | 0.07 |
Margins
Gross margin is 83.28%, with operating and profit margins of 12.45% and 7.19%.
| Gross Margin | 83.28% |
| Operating Margin | 12.45% |
| Pretax Margin | 10.79% |
| Profit Margin | 7.19% |
| EBITDA Margin | 13.72% |
| EBIT Margin | 12.45% |
| FCF Margin | 26.10% |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 4.17%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 4.17% |
| Dividend Growth (YoY) | 50.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 100.62% |
| Buyback Yield | -0.68% |
| Shareholder Yield | 3.49% |
| Earnings Yield | 4.14% |
| FCF Yield | 18.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NexgenRx has an Altman Z-Score of 1.23 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.23 |
| Piotroski F-Score | 6 |